US EditionNine of the largest pharma companies ink deals with Trump to lower drug prices
Fourteen of the 17 largest drugmakers, including nine new companies, agreed to cut prices and invest $150 billion in U.S. manufacturing, aiming to reduce U.S. drug costs linked to global prices.
- On Dec. 19, President Donald Trump announced deals with nine pharmaceutical companies to cut some U.S. drug prices in exchange for three-year tariff reprieves, with 14 of the 17 targeted drugmakers agreeing to lower Medicaid prices and sell discounted drugs.
- Motivated by U.S. price disparities, the administration pursues a Most Favored Nation push, with 14 of 17 drugmakers targeted by Trump agreeing to lower prices and mirror foreign agreements.
- Several companies committed to donations and emergency manufacturing, with Merck & Co., Bristol-Myers Squibb Co. and GSK pledging six months’ raw materials to a national stockpile.
- A White House briefing is set for Friday at 1 p.m. in the Roosevelt Room with at least five drugmakers, while Deputy Attorney General Todd Blanche said the Department of Justice will send Congress several hundred thousand documents that day.
- Democrats have demanded more details from companies on confidential tariff-relief deals as the Department of Justice met its Epstein-file release deadline, while White House Press Secretary Karoline Levitt said `Trump will be announcing more incredible deals that will lower prices of drugs and pharmaceuticals`.
219 Articles
219 Articles
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal - AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN)
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. costs into line with those of other wealthy countries. Bristol Myers Squibb Co. (NYSE:BMY), Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK), Genentech, Novartis AG (NYSE:NVS), Amgen Inc. (NASDAQ:AMGN), Boehringer Ingelheim, Sanofi SA (NA…
Drugmakers cut prices on most drugs sold to the US Medicaid program
US president Donald Trump and nine major pharmaceutical companies announced deals on Friday that will slash the prices of their medicines for the government's Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.
Trump, 9 drug companies strike deal to cut prescription prices | Honolulu Star-Advertiser
President Donald Trump and nine major pharmaceutical companies today announced deals that will slash the prices of their medicines for the government’s Medicaid program and for cash payers, in his latest bid to align U.S. costs with those in other wealthy nations.
Trump's 9 New Prescription Drug Deals 'No Substitute' for Systemic Reform
In response to Trump's new deals with prescription drugmakers, one campaigner stressed that "voluntary agreements with drug companies—especially when key details remain undisclosed—are no substitute for durable, system-wide reforms."
The pharmaceutical companies that collaborate to lower the price are: Bristol Myers Squibb, Genentech, Boehringer Ingelheim, Sanofi, Novartis, Merck, Gilead, GSK and Amgem
Coverage Details
Bias Distribution
- 66% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
